A 18 September 2026 mouse experiment at UC Davis found Tac1-deficient animals shed less Citrobacter rodentium and carried a lower colon bacterial load than wild-type controls, with less tissue damage.
The desk card dated 18 September 2026 names Lloyd, Cremin and UC Davis colleagues. They used histopathology, qPCR and flow cytometry on a mouse gut infection with Citrobacter rodentium. The work is a rodent-gut experiment. It does not show that aiming at Tac1 treats a human bowel infection. Tac1 here is the gene that encodes sensory neuropeptides in that model.[1]
In the Tac1-deficient group, feces carried fewer of the challenge bacteria and the colon itself grew fewer colonies than wild-type cages. Inflammatory cytokine and chemokine expression was lower. Neutrophils, monocytes and colon T cells that make interferon-gamma or interleukin-17A arrived in smaller numbers. Tissue damage was markedly less. Those are the measurements on the retained desk card, not a human clinic note.[1]
The retained English detail limits the finding to a mouse intestine and refuses a leap to treating people with bowel infection by hitting Tac1. Nature News returned HTTP 404 on a guessed 2026 story URL for this paper. The Scientist returned HTTP 403 on a guessed news-opinion URL. No second independent publisher own page confirmed the same mouse counts.[1]
